ProShare Advisors
EWTX icon

ProShare Advisors’s Edgewise Therapeutics EWTX Stock Holding History

ProShare Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$524K Sell
12,890
-1,688
-12% -$58.2K ﹤0.01% 1063
2026
Q1 		$459K Sell
14,578
-2,398
-14% -$69.2K ﹤0.01% 1112
2025
Q4 		$421K Buy
16,976
+1,685
+11% +$33.8K ﹤0.01% 1231
2025
Q3 		$248K Sell
15,291
-3,597
-19% -$51K ﹤0.01% 1564
2025
Q2 		$248K Sell
18,888
-1,315
-7% -$19K ﹤0.01% 1577
2025
Q1 		$444K Sell
20,203
-4,725
-19% -$124K ﹤0.01% 1162
2024
Q4 		$666K Buy
24,928
+5,669
+29% +$181K ﹤0.01% 1108
2024
Q3 		$514K Buy
19,259
+5,769
+43% +$115K ﹤0.01% 1114
2024
Q2 		$243K Sell
13,490
-3,395
-20% -$59.2K ﹤0.01% 1425
2024
Q1 		$308K Buy
16,885
+5,748
+52% +$91.4K ﹤0.01% 1414
2023
Q4 		$122K Buy
+11,137
New +$78.2K ﹤0.01% 1753
2023
Q1 		– Sell
-10,105
Closed -$90.3K – 1832
2022
Q4 		$90.3K Buy
+10,105
New +$94.7K ﹤0.01% 1669
2022
Q2 		– Sell
-12,378
Closed -$120K – 1904
2022
Q1 		$120K Sell
12,378
-3,015
-20% -$38.8K ﹤0.01% 1997
2021
Q4 		$235K Buy
+15,393
New +$277K ﹤0.01% 1929

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ProShare Advisors's EWTX Position: Q2 2026 in Review

ProShare Advisors reduced its Edgewise Therapeutics (EWTX) stake by 12% in Q2 2026, selling an estimated $58.2K and leaving 12,890 shares worth $524K. The position accounts for ﹤0.01% of the portfolio, ranked #1063.

ProShare Advisors first reported a position in EWTX in Q4 2021 and has held it in 14 quarters since. The position peaked at $666K in Q4 2024. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • ProShare Advisors held 12,890 shares of Edgewise Therapeutics worth $524K as of Q2 2026.
  • ProShare Advisors sold 1,688 Edgewise Therapeutics shares in Q2 2026, an estimated $58.2K.
  • Edgewise Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1063 holding.
  • ProShare Advisors first reported a position in Edgewise Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • ProShare Advisors's Edgewise Therapeutics position peaked at $666K in Q4 2024.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.